Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone

Paul J. Hesketh, David R Gandara, Ann M. Hesketh, Martin Edelman, Lauri M. Webber, Matthew McManus, John D. Hainsworth

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

PURPOSE: To evaluate the antiemetic efficacy and safety of adding the dopamine antagonist prochlorperazine to the combination of granisetron and dexamethasone in the prevention of acute nausea and vomiting following high- dose cisplatin. PATIENTS AND METHODS: Sixty patients receiving cisplatin (≤ 75 mg/m2) (median dose = 100 mg/m2) were enrolled at three sites. Patients received prochlorperazine spansule 15 mg orally, 60 minutes prior to and 12 hours after cisplatin; dexamethasone 20 mg intravenously, 45 minutes prior to cisplatin, and 10 mg intravenously or orally, 12 hours after cisplatin; and granisetron 10 μg/kg intravenously, 30 minutes prior to cisplatin. Efficacy was assessed during the 24-hour period after cisplatin using complete antiemetic response (no emetic episodes and no rescue antiemetics) and patient assessment of nausea and satisfaction using 100-mm visual analog scales (nausea: 0 = none, 100 = nausea as bad as it can be; satisfaction: 0 = not at all satisfied, 100 = satisfied as can be). RESULTS: Complete response (0 emetic episodes) was noted in 84% (49/58) of patients. Forty-two patients (72%) experienced no nausea. The mean change in posttreatment nausea visual analog scales from baseline was 8.9 mm. Forty-eight patients (83%) were completely satisfied with their antiemetic treatment. The mean posttreatment patient satisfaction score was 92 mm. Treatment was well tolerated, with infrequent and minor adverse events. CONCLUSIONS: This three-drug antiemetic regimen is well tolerated and highly effective in the prevention of acute nausea and vomiting arising from high-dose cisplatin. Further studies evaluating this regimen are warranted.

Original languageEnglish (US)
Pages (from-to)180-183
Number of pages4
JournalCancer Journal from Scientific American
Volume3
Issue number3
StatePublished - 1997

Fingerprint

Prochlorperazine
Granisetron
Dexamethasone
Cisplatin
Vomiting
Nausea
Antiemetics
Emetics
Visual Analog Scale
Trimeprazine
Dopamine Antagonists
Patient Satisfaction
Safety

Keywords

  • 5-hydroxytryptamine receptor antagonists
  • Antiemetics
  • cisplatin
  • dexamethasone
  • granisetron
  • prochlorperazine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone. / Hesketh, Paul J.; Gandara, David R; Hesketh, Ann M.; Edelman, Martin; Webber, Lauri M.; McManus, Matthew; Hainsworth, John D.

In: Cancer Journal from Scientific American, Vol. 3, No. 3, 1997, p. 180-183.

Research output: Contribution to journalArticle

Hesketh, Paul J. ; Gandara, David R ; Hesketh, Ann M. ; Edelman, Martin ; Webber, Lauri M. ; McManus, Matthew ; Hainsworth, John D. / Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone. In: Cancer Journal from Scientific American. 1997 ; Vol. 3, No. 3. pp. 180-183.
@article{bbd56f435e264e7f8b8b9bf5715da269,
title = "Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone",
abstract = "PURPOSE: To evaluate the antiemetic efficacy and safety of adding the dopamine antagonist prochlorperazine to the combination of granisetron and dexamethasone in the prevention of acute nausea and vomiting following high- dose cisplatin. PATIENTS AND METHODS: Sixty patients receiving cisplatin (≤ 75 mg/m2) (median dose = 100 mg/m2) were enrolled at three sites. Patients received prochlorperazine spansule 15 mg orally, 60 minutes prior to and 12 hours after cisplatin; dexamethasone 20 mg intravenously, 45 minutes prior to cisplatin, and 10 mg intravenously or orally, 12 hours after cisplatin; and granisetron 10 μg/kg intravenously, 30 minutes prior to cisplatin. Efficacy was assessed during the 24-hour period after cisplatin using complete antiemetic response (no emetic episodes and no rescue antiemetics) and patient assessment of nausea and satisfaction using 100-mm visual analog scales (nausea: 0 = none, 100 = nausea as bad as it can be; satisfaction: 0 = not at all satisfied, 100 = satisfied as can be). RESULTS: Complete response (0 emetic episodes) was noted in 84{\%} (49/58) of patients. Forty-two patients (72{\%}) experienced no nausea. The mean change in posttreatment nausea visual analog scales from baseline was 8.9 mm. Forty-eight patients (83{\%}) were completely satisfied with their antiemetic treatment. The mean posttreatment patient satisfaction score was 92 mm. Treatment was well tolerated, with infrequent and minor adverse events. CONCLUSIONS: This three-drug antiemetic regimen is well tolerated and highly effective in the prevention of acute nausea and vomiting arising from high-dose cisplatin. Further studies evaluating this regimen are warranted.",
keywords = "5-hydroxytryptamine receptor antagonists, Antiemetics, cisplatin, dexamethasone, granisetron, prochlorperazine",
author = "Hesketh, {Paul J.} and Gandara, {David R} and Hesketh, {Ann M.} and Martin Edelman and Webber, {Lauri M.} and Matthew McManus and Hainsworth, {John D.}",
year = "1997",
language = "English (US)",
volume = "3",
pages = "180--183",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone

AU - Hesketh, Paul J.

AU - Gandara, David R

AU - Hesketh, Ann M.

AU - Edelman, Martin

AU - Webber, Lauri M.

AU - McManus, Matthew

AU - Hainsworth, John D.

PY - 1997

Y1 - 1997

N2 - PURPOSE: To evaluate the antiemetic efficacy and safety of adding the dopamine antagonist prochlorperazine to the combination of granisetron and dexamethasone in the prevention of acute nausea and vomiting following high- dose cisplatin. PATIENTS AND METHODS: Sixty patients receiving cisplatin (≤ 75 mg/m2) (median dose = 100 mg/m2) were enrolled at three sites. Patients received prochlorperazine spansule 15 mg orally, 60 minutes prior to and 12 hours after cisplatin; dexamethasone 20 mg intravenously, 45 minutes prior to cisplatin, and 10 mg intravenously or orally, 12 hours after cisplatin; and granisetron 10 μg/kg intravenously, 30 minutes prior to cisplatin. Efficacy was assessed during the 24-hour period after cisplatin using complete antiemetic response (no emetic episodes and no rescue antiemetics) and patient assessment of nausea and satisfaction using 100-mm visual analog scales (nausea: 0 = none, 100 = nausea as bad as it can be; satisfaction: 0 = not at all satisfied, 100 = satisfied as can be). RESULTS: Complete response (0 emetic episodes) was noted in 84% (49/58) of patients. Forty-two patients (72%) experienced no nausea. The mean change in posttreatment nausea visual analog scales from baseline was 8.9 mm. Forty-eight patients (83%) were completely satisfied with their antiemetic treatment. The mean posttreatment patient satisfaction score was 92 mm. Treatment was well tolerated, with infrequent and minor adverse events. CONCLUSIONS: This three-drug antiemetic regimen is well tolerated and highly effective in the prevention of acute nausea and vomiting arising from high-dose cisplatin. Further studies evaluating this regimen are warranted.

AB - PURPOSE: To evaluate the antiemetic efficacy and safety of adding the dopamine antagonist prochlorperazine to the combination of granisetron and dexamethasone in the prevention of acute nausea and vomiting following high- dose cisplatin. PATIENTS AND METHODS: Sixty patients receiving cisplatin (≤ 75 mg/m2) (median dose = 100 mg/m2) were enrolled at three sites. Patients received prochlorperazine spansule 15 mg orally, 60 minutes prior to and 12 hours after cisplatin; dexamethasone 20 mg intravenously, 45 minutes prior to cisplatin, and 10 mg intravenously or orally, 12 hours after cisplatin; and granisetron 10 μg/kg intravenously, 30 minutes prior to cisplatin. Efficacy was assessed during the 24-hour period after cisplatin using complete antiemetic response (no emetic episodes and no rescue antiemetics) and patient assessment of nausea and satisfaction using 100-mm visual analog scales (nausea: 0 = none, 100 = nausea as bad as it can be; satisfaction: 0 = not at all satisfied, 100 = satisfied as can be). RESULTS: Complete response (0 emetic episodes) was noted in 84% (49/58) of patients. Forty-two patients (72%) experienced no nausea. The mean change in posttreatment nausea visual analog scales from baseline was 8.9 mm. Forty-eight patients (83%) were completely satisfied with their antiemetic treatment. The mean posttreatment patient satisfaction score was 92 mm. Treatment was well tolerated, with infrequent and minor adverse events. CONCLUSIONS: This three-drug antiemetic regimen is well tolerated and highly effective in the prevention of acute nausea and vomiting arising from high-dose cisplatin. Further studies evaluating this regimen are warranted.

KW - 5-hydroxytryptamine receptor antagonists

KW - Antiemetics

KW - cisplatin

KW - dexamethasone

KW - granisetron

KW - prochlorperazine

UR - http://www.scopus.com/inward/record.url?scp=0030953660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030953660&partnerID=8YFLogxK

M3 - Article

C2 - 9161784

AN - SCOPUS:0030953660

VL - 3

SP - 180

EP - 183

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 3

ER -